ReviewJornal brasileiro de nefrologia

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.

Vikas S Sridhar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.